3rd Quarter - Report

VIR BIOTECHNOLOGY, INC. for VIR BIOTECHNOLOGY, INC.

Firm
Client
Income
—
Expenses
$150,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S. 3799 PREVENT Pandemics Act; Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurement; S. 2640 Disease X Act; S. 3258/H.R. 6025 Flu Vaccine Act; FY 2023 Labor-HHS Appropriations; H.R. 5376, Inflation Reduction Act

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Office of Science & Technology Policy (OSTP)

Bills named: S. 2640 (117th), H.R. 5376 (117th), S. 3258 (117th), H.R. 6025 (117th), S. 3799 (117th)

Science/Technology SCI

Pandemic Preparedness

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Natl Institutes of Health (NIH); Office of Science & Technology Policy (OSTP); Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

Coverage and Reimbursement of COVID-19 Therapeutics.

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Taxation/Internal Revenue Code TAX

H.R. 7410, American-Made Medicine Act; H.R. 7505, More Cures Act; Section 174 R&D Expensing; H.R. 1304, American Innovation and R&D Competitiveness Act

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 7505 (117th), H.R. 7410 (117th), H.R. 1304 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.